8,958 Results
AcrySof IQ PanOptix intraocular lens (IOL) shows superior visual outcomes to the ZEISS AT LISA tri 839MP IOL in head to head study of cataract patients.- Alcon.
Added ago
Alcon, unveils new data showing significantly improved near and intermediate distance vision with the AcrySof IQ PanOptix intraocular lens (IOL)...
FDA approves Memo 4D mitral annuloplasty ring for treatment of mitral regurgitation.- LivaNova.
Added 12 hours ago
LivaNova PLC a market-leading medical technology company, announced it received FDA 510(k) clearance for its MEMO 4D semi-rigid mitral annuloplasty...
FDA Advisory Committee recommends premarket approval for Incraft AAA Stent Graft System for infrarenal abdominal aortic aneurysms. - Cordis/Cardinal Health.
Added 12 hours ago
Cardinal Health announced that the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee has provided a favorable...
CE Mark for CleanCision wound retraction and protection system.- Prescient Surgical,
Added 12 hours ago
Prescient Surgical announced it received CE Mark approval for its first-in-class, advanced technology CleanCision which fights and defends against the...
QuANTUM-R phase III study of AC 220 shows benefits for overall survival in acute myeloid leukemia.- Daiichi Sankyo.
Added 12 hours ago
Daiichi Sankyo announced updated positive results from the pivotal QuANTUM-R phase III study of AC 220 (quizartinib) which showed that...
Complete Response Letter for Furoscix, a proposed treatment of edema or fluid overload in patients with heart failure.- sc Pharmaceuticals.
Added 1 day ago
scPharmaceuticals Inc., announced the Company received a Complete Response Letter (CRL) from the FDA regarding the 505(b)(2) application for Furoscix,...
Teva discontinues the ENFORCE trial of fremanezumab for chronic cluster headache but the episodic cluster headache part of the study continues as planned.
Added 1 day ago
Teva Pharmaceutical Industries Ltd. announced a change in the clinical development program of fremanezumab in chronic cluster headache . The...
Fourteen months results from JULIET trial of Kymriah for patients with DLBCL.- Novartis
Added 1 day ago
Novartis announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah (tisagenlecleucel) when...
Dexcom G6 continuous glucose monitor for diabetes receives CE Mark.- Dexcom.
Added 1 day ago
Dexcom, Inc. a leader in continuous glucose monitoring (CGM), announced that the company has received CE Mark for its Dexcom...
Phase III MURANO trial of Venclexta + Rituxan shows detection limits of disease in chronic lymphocytic leukemia.- AbbVie/Roche/Genentech.
Added 2 days ago
AbbVie announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the...